United Capital Financial Advisors LLC Boosts Stock Position in Elevance Health, Inc. $ELV

Posted by George Bondi on Aug 29th, 2026

United Capital Financial Advisors LLC boosted its position in Elevance Health, Inc. (NYSE:ELV – Free Report) by 15.7% in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 9,403 shares of the company’s stock after purchasing an additional 1,275 shares during the quarter. United Capital Financial Advisors LLC’s holdings in Elevance Health were worth $3,636,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Kilter Group LLC bought a new position in shares of Elevance Health during the 2nd quarter worth approximately $28,000. Kemnay Advisory Services Inc. acquired a new stake in Elevance Health in the fourth quarter valued at approximately $31,000. J.Safra Asset Management Corp acquired a new stake in Elevance Health in the fourth quarter valued at approximately $32,000. WealthCollab LLC grew its holdings in Elevance Health by 42.2% in the first quarter. WealthCollab LLC now owns 91 shares of the company’s stock worth $27,000 after purchasing an additional 27 shares during the last quarter. Finally, Elevation Wealth Partners LLC grew its holdings in Elevance Health by 600.0% in the second quarter. Elevation Wealth Partners LLC now owns 105 shares of the company’s stock worth $41,000 after purchasing an additional 90 shares during the last quarter. 89.24% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on ELV shares. Bank of America increased their price objective on Elevance Health from $435.00 to $460.00 and gave the company a “buy” rating in a report on Thursday, June 4th. The Goldman Sachs Group restated a “neutral” rating and set a $395.00 target price on shares of Elevance Health in a research note on Thursday, July 16th. Cantor Fitzgerald upped their target price on Elevance Health from $400.00 to $450.00 and gave the company an “overweight” rating in a research report on Tuesday, July 7th. Wall Street Zen cut Elevance Health from a “buy” rating to a “hold” rating in a research note on Sunday, July 12th. Finally, UBS Group raised their price target on Elevance Health from $400.00 to $460.00 and gave the stock a “buy” rating in a report on Friday, May 22nd. Fifteen analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $440.90.

Get Our Latest Research Report on ELV

Insiders Place Their Bets

In other Elevance Health news, Director Robert L. Dixon, Jr. sold 151 shares of the business’s stock in a transaction dated Thursday, June 11th. The stock was sold at an average price of $401.77, for a total transaction of $60,667.27. Following the sale, the director owned 10,734 shares in the company, valued at approximately $4,312,599.18. The trade was a 1.39% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 0.34% of the company’s stock.

Elevance Health Trading Down 1.0%

NYSE ELV opened at $395.28 on Friday. The company has a fifty day simple moving average of $395.36 and a two-hundred day simple moving average of $362.06. The stock has a market cap of $85.72 billion, a P/E ratio of 17.57, a P/E/G ratio of 2.28 and a beta of 0.68. Elevance Health, Inc. has a 12-month low of $274.84 and a 12-month high of $436.24. The company has a current ratio of 1.52, a quick ratio of 1.52 and a debt-to-equity ratio of 0.68.

Elevance Health (NYSE:ELV – Get Free Report) last posted its quarterly earnings data on Wednesday, July 15th. The company reported $7.45 EPS for the quarter, topping the consensus estimate of $6.21 by $1.24. The business had revenue of $49.83 billion during the quarter, compared to the consensus estimate of $48.88 billion. Elevance Health had a net margin of 2.47% and a return on equity of 14.64%. The business’s revenue for the quarter was up .8% compared to the same quarter last year. During the same period in the previous year, the firm posted $8.84 earnings per share. On average, analysts forecast that Elevance Health, Inc. will post 27.18 earnings per share for the current year.

Elevance Health Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, September 25th. Shareholders of record on Thursday, September 10th will be given a dividend of $1.72 per share. The ex-dividend date of this dividend is Thursday, September 10th. This represents a $6.88 dividend on an annualized basis and a yield of 1.7%. Elevance Health’s payout ratio is currently 30.58%.

Elevance Health Profile

(Free Report)

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.